BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 31346778)

  • 21. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
    Bast RC
    Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Status of tumor markers in ovarian cancer screening.
    Bast RC
    J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ
    Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.
    Stiekema A; Lok CA; Kenter GG; van Driel WJ; Vincent AD; Korse CM
    Gynecol Oncol; 2014 Mar; 132(3):573-7. PubMed ID: 24418200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    Rosenthal AN; Fraser LSM; Philpott S; Manchanda R; Burnell M; Badman P; Hadwin R; Rizzuto I; Benjamin E; Singh N; Evans DG; Eccles DM; Ryan A; Liston R; Dawnay A; Ford J; Gunu R; Mackay J; Skates SJ; Menon U; Jacobs IJ;
    J Clin Oncol; 2017 May; 35(13):1411-1420. PubMed ID: 28240969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.
    Gu Z; He Y; Zhang Y; Chen M; Song K; Huang Y; Li Q; Di W
    J Transl Med; 2018 May; 16(1):114. PubMed ID: 29716620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of biomarker systems as an alternative for early diagnosis of ovarian carcinoma.
    Srivastava A; Gupta A; Patidar S
    Clin Transl Oncol; 2021 Oct; 23(10):1967-1978. PubMed ID: 33840014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
    Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
    Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
    van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ
    Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
    Xi QP; Pu DH; Lu WN
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probability of fallopian tube and ovarian detection with transvaginal ultrasonography in normal women.
    Lefringhouse JR; Neward E; Ueland FR; Baldwin LA; Miller RW; DeSimone CP; Kryscio RJ; van Nagell JR; Pavlik EJ
    Womens Health (Lond); 2016 Jun; 12(3):303-11. PubMed ID: 27189894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
    Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; MariƱo IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
    Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination of Sonographic Morphology Score and Tumor Markers for Detecting Postoperative Recurrent Pelvic Ovarian Carcinoma: Compared With MRI Assessment.
    Shen ZY; Shen AJ; Yang SL; Wu MF
    Ultrasound Q; 2019 Mar; 35(1):45-53. PubMed ID: 30672869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.
    Kaijser J; Van Gorp T; Van Hoorde K; Van Holsbeke C; Sayasneh A; Vergote I; Bourne T; Timmerman D; Van Calster B
    Gynecol Oncol; 2013 May; 129(2):377-83. PubMed ID: 23360924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.